Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hepatitis b antibodies

An antibody, human antibody technology, applied in the direction of antibodies, antiviral agents, antiviral immunoglobulins, etc., can solve problems such as inability to eliminate viruses

Pending Publication Date: 2021-01-01
NOVARTIS AG
View PDF75 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although nucleosides inhibit HBV DNA polymerase activity with varying potency and resistance barriers, this therapy does not eliminate the virus and patients remain on this therapy for life

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hepatitis b antibodies
  • Hepatitis b antibodies
  • Hepatitis b antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0286] Example 1: Generation of anti-HBsAg viral antibodies

[0287] Human memory B cells from HBV-vaccinated donors were expanded in vitro and selected for their ability to secrete IgG antibodies against HBsAg. Specific B cells were lysed and the VH (heavy) and VL (light) chains were amplified by RT-PCR and then sequenced and analyzed to identify key post-translational modification (PTM) sites. The plasmids for the VH and VL chains are then transfected into an IgG1 backbone vector in a CHO mammalian cell line to express intact IgG1 antibodies.

[0288]Methods for generating monoclonal antibodies using phage display technology are known in the art (Antibody Methods and Protocols, Methods in Molecular Biology Vol. 901, 2012, Chapter 3:33). Briefly, by complexing with biotinylated recombinant HBsAg (TRINA Bioreactives AG, Cat. No. C028-3001994774 (AD serotype), C028-3001994774 (AY serotype) or Biorbyte, Cat. No. orb82536 (AD isotype)) Solution panning with streptavidin-conju...

example 2

[0294] Example 2: Binding of anti-HBsAg antibody to HBsAg

[0295] Surface plasmon resonance (SPR) was used to determine the binding affinity interactions (K D ). HBsAg particles were immobilized on the S-series CM5 sensor chip at approximately 800 RU, and anti-HBsAg antibodies were flowed in 2-fold serial dilutions starting from 128 nM to utilize a Biacore T200 instrument (GEHeathcare, catalog number 28975001, Pittsburgh, Pennsylvania) assesses the combination. K was determined by fitting the curve with a 1:1 fit model D (O'Shannessy et al. Anal.Biochem [Analytical Biochemistry] 1993; 212:457-468; Karlsson, J. Immunol. Methods. 1997; 200:121-133).

[0296] K of anti-HBsAg antibody measured by Biacore D Values ​​ranged from 110 pM to 40 nM and were comparable between the two major serotypes (AD and AY) for each antibody tested. The Biacore affinity data summary of the anti-HBsAg antibody is shown in Table 4, and the SPR curve is shown in figure 1 A / B-16A / B.

[029...

example 3

[0300] Example 3: Neutralization of hepatitis B virus infection by anti-HBsAg antibodies

[0301] Infectious HBV virus was purified from genotype D, serotype ayw cell culture-derived HBV as described (Meier et al., J. Virol Hepat. 2017;24:662-671). Anti-HBsAg antibodies were pre-incubated with virus for 1 hour at 37°C to allow binding and neutralization. HepG2-hNTCP1 cells generated in-house as described (Tropberger et al, Proc. Fresh medium was replaced and incubated for an additional 6 days to allow virus entry, cccDNA establishment and viral protein expression. Supernatants were recovered and analyzed for HBeAg levels by a custom in-house eAg AlphaScreen assay (Perkin Elmer, Bridgeville, PA). Data were analyzed using an Envision plate reader (PerkinElmer, Cat. No. 2105-0010, Bridgeville, PA) and expressed as percent infection relative to untreated control wells.

[0302] All antibodies were able to neutralize HBV infection, EC 50 Values ​​ranged from 17pM to 740pM, an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to anti-HBsAg antibodies, antibody fragments, and their uses for the prevention and treatment of hepatitis B virus infection and associated diseases.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to U.S. Serial No. 62 / 678,756, filed May 31, 2018, the contents of which are incorporated herein by reference. technical field [0003] The present disclosure relates to anti-hepatitis B surface antigen antibodies, antibody fragments and uses thereof for reducing the likelihood or treatment of hepatitis B virus infection. Background technique [0004] Hepatitis B virus (HBV) is an enveloped, hepatotropic virus that infects the liver and can cause chronic hepatitis B (CHB), cirrhosis, and hepatocellular carcinoma (HCC). Although there is a safe vaccine against HBV, at least 600,000 people worldwide die each year from HBV-related disorders. Disease progression is influenced by viral load, genotype, and specific viral mutations (Biswas et al., Med. Virol. 2013;85:1340-1347). HBV is classified into ten genotypes or into four serotypes (asw, adr, ayw, and ayr) based on epit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P31/20C07K16/08
CPCA61K2039/505A61P31/20C07K16/082C07K2317/21C07K2317/30C07K2317/33C07K2317/55C07K2317/76C07K2317/92
Inventor S·埃韦特M·M·霍尔多夫E·特拉吉埃
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com